Outcome and Cost of Colistin and Tigecycline for Treatment of Gram-Negative Infections
Article Sidebar
Main Article Content
Abstract
Objective: This study aimed to determine outcome and cost of colistin and tigecycline for treatment of gram-negative infections. Methods: Data were retrospectively collected from electronic database of patients who hospitalized in Mahasarakham Hospital between January and June of 2012. Patient characteristics, treatment outcome and cost were analyzed with appropriate statistics. Results: There were 70 patients: 40 patients receiving colistin and 30 patients receiving tigecycline. Most of them had infection with Acinebacter baumannii (100% vs. 90%). Proportion of patients with clinical improvement was higher in patients with colistin treatment than tigecycline treatment (47.5% vs. 33.3%, p=0.234). When controlling for sex, age, sepsis, ICU treatment and receiving other antibiotics, clinical improvement in patients with colistin treatment was not different from that in patients with tigecycline treatment (adjusted OR = 1.390, 95%CI 0.313 - 6.173, p=0.665). Median medication cost per patient in patients receiving colistin was lower than patients receiving tigecycline (2,640 baht vs. 37,437 baht, p<0.001). Conclusion: The findings of this study indicate that colistin and tigecycline treatment for gram-negative infections have no different outcome but treatment with colistin will reduce medication cost rather than treatment with tigecycline.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Abbo A, Carmeli Y, Navon-Venezia S, et al. Impact of multi-drug-resistant Acinetobacter baumanniion clinical outcomes. Eur J Clin Microbiol Infect Dis 2007; 26(11): 793-800.
Cai Y, Wang R, Liang B, et al., Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemoter 2012; 67(7): 1607-15.
Chang KC, Lin MF, Lin NT, et al. Clonal spread of multidrug-resistant Acinetobacter baumanniiin eastern Taiwan. J Microbiol Immunol Infect 2012; 45: 37-42.
Drug System Monitoring Mechanism Development Program. Annual Report on Drug System Situation 2010: Drug-Resistant and Antibiotic Use Problems. Bangkok: Drug System Monitoring Mechanism Development Program. 2011. [in Thai]
Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68: 140–151.
FDA Drug Safety Communication. Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm. Accessed November 15, 2012.
Giamarellou H, Poulakou G. Multidrug-Resistant Gram-Negative Infections: What are the treatment Options? Drugs 2009; 69 (14): 1879-1901.
Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63: 775–80.
Karageorgopoulos D, Kelesidis T, Kelesidis I et al.Tigecycline for the treatment of multidrug-resistant (including carbapenemresistant) Acinetobacter infections: a review of the scientifi c evidence. J Antimicrob Chemother 2008; 62: 45–55.
Koomanachai P, Tiengrim S, Kiratisin P, et al. Effi cacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007; 11(5): 402-6.
Ku K, Pogue JM, Moshos J, et al. Retrospective evaluation of colistin and tigecycline for treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacter infections. American Journal of Infection Control 2012; doi:10.1016/j.ajic.2011.12.014.
McDonald LC. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis 2006; 42 Suppl. 2: S65-71.
National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32 (8): 470-85.
Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect2005; 11 Suppl. 4: 17-32
Shin JA, Chang YS, Kim HJ, et al. Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection. Yonsei Med J 2012; 53(5): 974-84.
Spapen H, Jacobs R, Gorp VV, et al., Renal and neu-rological side effeects of colistin in critically ill patients. Ann Intensive Care 2011; 1: 14. doi: 10.1186/2110-5820-1-14
Thamlikitkul V. Colistin: Antimicrobials for Treatment of Drug Resistant Gram-Negative Infections. Siriraj Medical Journal 2008; 1(3): 152-8. [in Thai]